{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:12:21Z","timestamp":1778825541163,"version":"3.51.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenem-resistant organisms (CRO) cause significant morbidity and mortality, with a rising incidence worldwide. Immunosuppression, prolonged hospitalization, and extensive use of broad-spectrum antibiotics make allogeneic hematopoietic cell transplant (alloHCT) recipients particularly susceptible. This study evaluated the impact of peri-transplant CRO infections on alloHCT outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of adult alloHCT recipients between 2015 and 2024. CRO infection was defined as occurring within 12 months of alloHCT. Using 1:3 propensity score matching, patients with CRO were matched to controls by age, sex, year of transplant, stem cell source, donor type, and diagnosis. Overall survival (OS) and non-relapse mortality (NRM) were analyzed using Kaplan\u2013Meier methods and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 171 patients were included: 43 with CRO and 128 controls; 53.4% of CRO cases occurred in the last 3 years. Median age was 35 years, 66.7% were male, and 89.5% underwent transplant for malignant disease. Matched-related donors were used in 79.5%, peripheral blood stem cells in 88.3%, and myeloablative conditioning in 70.2%. Median follow-up was 27 months. CRO patients had higher ICU admission rates (30.2% vs. 17.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.067) and lower 1-year OS (46.5% vs. 72.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). On multivariate analysis, CRO infection was independently associated with worse OS, while engraftment predicted improved OS and lower NRM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CRO infections remain an increasing challenge in alloHCT and are associated with higher ICU admission, increased NRM, and inferior survival, highlighting the need for improved prevention and management strategies<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frtra.2026.1818037","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:16Z","timestamp":1778823736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of allogeneic hematopoietic cell transplantation in patients with carbapenem-resistant organisms infection: a propensity score-matched analysis"],"prefix":"10.3389","volume":"5","author":[{"given":"Abeer","family":"Yaseen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teeba","family":"Mubaydeen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem","family":"Al-qaraleh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Otoom","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadee","family":"Shaban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazim","family":"Mesmar","sequence":"additional","affiliation":[{"name":"University of Jordan, School of Medicine","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albatoul","family":"Alomoush","sequence":"additional","affiliation":[{"name":"Office of Scientific Affairs and Research, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Da'Na","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Abu Jazar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa","family":"Saadeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]},{"name":"University of Jordan, School of Medicine","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ma'koseh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]},{"name":"University of Jordan, School of Medicine","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Shamieh","sequence":"additional","affiliation":[{"name":"University of Jordan, School of Medicine","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Kullab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Abu Ata","sequence":"additional","affiliation":[{"name":"Office of Scientific Affairs and Research, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joud","family":"Jarrah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Abdel Rahman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]},{"name":"University of Jordan, School of Medicine","place":["Amman, Jordan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.2147\/IDR.S387615","article-title":"Active screening of intestinal colonization of carbapenem-resistant Enterobacteriaceae for subsequent bloodstream infection in allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Cao","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e14172","DOI":"10.1111\/ctr.14172","article-title":"Infectious complications in allogeneic hematopoietic cell transplant recipients: review of transplant-related risk factors and current state of prophylaxis","volume":"35","author":"Akhmedov","year":"2021","journal-title":"Clin Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.transproceed.2017.03.081","article-title":"Infectious complications and multidrug-resistant Bacteria in patients with hematopoietic stem cell transplantation in the first 12 months after transplant","volume":"49","author":"C\u00e9sar-Arce","year":"2017","journal-title":"Transplant Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ejh.12859","article-title":"Multidrug-resistant organisms in allogeneic hematopoietic cell transplantation","volume":"98","author":"Heidenreich","year":"2017","journal-title":"Eur J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e12762","DOI":"10.1111\/tid.12762","article-title":"Multidrug-resistant Enterobacteriaceae, P seudomonas aeruginosa, and vancomycin-resistant Enterococcus\u202f: three major threats to hematopoietic stem cell transplant recipients","volume":"19","author":"Satlin","year":"2017","journal-title":"Transpant Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/bmt.2014.231","article-title":"Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy","volume":"50","author":"Girmenia","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/00365548.2013.857042","article-title":"Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21505594.2016.1213472","article-title":"Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies","volume":"8","author":"Pouch","year":"2017","journal-title":"Virulence"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20499361211053480","DOI":"10.1177\/20499361211053480","article-title":"Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation","volume":"8","author":"Sahitya","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.2147\/IDR.S424048","article-title":"Risk factors for carbapenem-resistant Enterobacteriaceae colonization and the effect on clinical outcomes and prognosis in allogeneic hematopoietic stem cell transplanted patients","volume":"16","author":"Wu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B13","article-title":"2019 Antibiotic resistance threats report","year":""},{"key":"B14","article-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","article-title":"Carbapenem-resistant Enterobacterales (CRE) Infection Control","year":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S1473-3099(22)00683-1","article-title":"The WHO AWaRe antibiotic book: providing guidance on optimal use and informing policy","volume":"22","author":"Sharland","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12350-017-1012-y","article-title":"Reducing bias using propensity score matching","volume":"25","author":"Morgan","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.05.027","article-title":"Incidence, risk factors, and outcomes of bloodstream infection during conditioning phase before allogeneic hematopoietic stem cell transplantation","author":"Pan","year":"2025","journal-title":"Transplant Cell. Ther"},{"key":"B24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-9034-4_11","article-title":"Infections in allogeneic stem cell transplantation","volume-title":"Principles and Practice of Transplant Infectious Diseases","author":"Pereira","year":"2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"50.e1","DOI":"10.1016\/j.jtct.2021.10.008","article-title":"Bloodstream infections and outcomes following allogeneic hematopoietic cell transplantation: a single-center study","volume":"28","author":"Carreira","year":"2022","journal-title":"Transplant Cellular Therapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"850.e1","DOI":"10.1016\/j.jtct.2022.09.001","article-title":"Bacterial bloodstream infections in patients undergoing allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cellular Therapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"269.e1","DOI":"10.1016\/j.jtct.2025.02.010","article-title":"Bloodstream infections and colonization in hematopoietic stem cell transplant recipients at a South African center: a retrospective analysis","volume":"31","author":"Van Leeuwen","year":"2025","journal-title":"Transplant Cellular Therapy"},{"key":"B28","volume-title":"Global Antimicrobial Resistance and use Surveillance System (GLASS) Report 2022","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"m1983","DOI":"10.1136\/bmj.m1983","article-title":"How COVID-19 is accelerating the threat of antimicrobial resistance","volume":"369","author":"Hsu","year":"2020","journal-title":"Br Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1093\/jac\/dkab300","article-title":"Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey","volume":"76","author":"Tomczyk","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evidence"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45.e1","DOI":"10.1016\/j.jtct.2021.09.020","article-title":"Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications\u2013A single center experience from India","volume":"28","author":"George","year":"2022","journal-title":"Transplant Cellular Therapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1223824","DOI":"10.3389\/fcimb.2023.1223824","article-title":"Clinical characteristics and mortality risk factors of mixed bacterial infections in hematopoietic stem cell transplantation recipients","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.2023.283175","article-title":"Allogeneic hematopoietic stem cell transplantation in patients aged 60\u201379 years in Germany (1998\u20132018): a registry study","volume":"109","author":"Weller","year":"2023","journal-title":"Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ofaf516","DOI":"10.1093\/ofid\/ofaf516","article-title":"Pre-hematopoietic stem cell transplantation colonization with carbapenem-resistant enterobacterales increases the risk of subsequent bacteremia in transplant recipients","volume":"12","author":"Kang","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/cid\/cix252","article-title":"Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study","volume":"65","author":"Bilinski","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.3389\/fcimb.2021.684659","article-title":"Faecal microbiota transplantation for multi-drug resistant organisms in haematopoietic stem cell transplant recipients","volume":"11","author":"Innes","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B42","article-title":"Drug Approval Package: AVYCAZ (ceftazidime-avibactam) Injection","year":""},{"key":"B43","article-title":"Label: VABOMERE (meropenem-vaborbactam)","year":"2017"},{"key":"B44","article-title":"Label: Recarbrio (imipenem-cilastatin\u2009+\u2009relebactam)","year":"2019"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e00682","DOI":"10.1128\/AAC.00682-18","article-title":"Plasma and intrapulmonary concentrations of cefepime and zidebactam following intravenous administration of WCK 5222 to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","article-title":"Discovery of taniborbactam (VNRX-5133): a broad-Spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e02229","DOI":"10.1128\/AAC.02229-19","article-title":"Safety and pharmacokinetic characterization of nacubactam, a novel \u03b2-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers","volume":"64","author":"Mallalieu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage therapy: a renewed approach to combat antibiotic-resistant bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: an alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jiph.2016.02.002","article-title":"Detection of OXA-48-like and NDM carbapenemases producing Klebsiella pneumoniae in Jordan: a pilot study","volume":"10","author":"Aqel","year":"2017","journal-title":"J Infect Public Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1128\/AAC.02050-13","article-title":"Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the gulf cooperation council: dominance of OXA-48 and NDM producers","volume":"58","author":"Zowawi","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1818037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:18Z","timestamp":1778823738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1818037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":53,"alternative-id":["10.3389\/frtra.2026.1818037"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2026.1818037","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1818037"}}